18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches. We propose to conduct a prospective study to evaluate early therapeutic response using 18F-FDG PET before and after the 1st cycle of neo-adjuvant chemotherapy for breast cancer patients. Variation of 18F-FDG PET uptake is compared to clinical and echographical tumor response evaluated after 3 cycles of chemotherapy. The purpose is to estimate the capacity of 18F-FDG PET to differentiate responder and non-responder patients.
Further study details as provided by Centre Oscar Lambret
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
63
370 MBq of FDG one hour before imaging acquisition PET just before neo-adjuvant chemotherapy and just before the second cycle
Centre Oscar Lambret
Lille, France
Variation rate of SUV(BSA max)before and after the 1st cycle of neoadjuvant chemotherapy
Time frame: before and 3 weeks after 1st cycle
Comparison to clinical and ultrasound assessment after the 3rd cycle of chemotherapy
Time frame: 3 weeks after the 3rd cycle
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.